Clayface: R-Rated DCU Horror Thriller Locks October 2026 Release

DC Studios is taking its Gotham underworld into hard-R territory with Clayface, a horror thriller that Warner Bros. Pictures will release internationally on October 21, 2026, and in North America on October 23, 2026, including IMAX engagements. The film carries an R rating for strong bloody violence, gore, language, some nudity, and brief drug use, a deliberate escalation for a franchise that has largely operated within the PG-13 theatrical lane.

The project marks the third theatrical entry in the James Gunn and Peter Safran era, positioning the shape-shifting villain as a test case for how far the studio’s tonal range can stretch. With Matt Reeves producing alongside Gunn and Safran, the film bridges the grounded crime textures of the Reeves Batman universe with the broader DCU architecture.

Body Horror Over Capes: James Watkins Builds a Practical Transformation

Director James Watkins inherits a screenplay from Mike Flanagan and Hossein Amini, with Flanagan credited for the story. The narrative follows Matt Hagen, a rising Hollywood actor whose disfigurement propels him toward the Clayface transformation, a premise that trades superhero spectacle for body horror and psychological decay. Tom Rhys Harries leads as Hagen, with Naomi Ackie as Dr. Caitlyn Corr, the scientist he turns to after his physical collapse.

Watkins is no stranger to visceral, contained terror, and the material demands practical transformation work rather than clean digital augmentation. Max Minghella’s Gotham detective John Borrelli and Corr’s fiancé subplot suggest the film will thread investigative procedure through its horror spine, echoing the kind of genre cross-pollination monitored across our theatrical release tracking. The R rating is not decorative, the descriptors point to a film willing to show the damage.

Calendar Leverage: Why Halloween Is the Right Bet for a Villain Origin

The October 21 international and October 23 domestic dates land squarely in the pre-Halloween horror corridor, a window that has repeatedly rewarded R-rated genre plays with outsized opening multiples. Warner Bros. is not chasing a four-day federal holiday; it is chasing the seasonal appetite for horror that peaks in late October. The IMAX component adds a premium-format revenue layer that villain-driven origin stories rarely secure.

Eddie Marsan, David Dencik, Nancy Carroll, and Joshua James round out a cast built for character density rather than star-wattage stacking. Executive producers Michael E. Uslan, Chantal Nong Vo, Lars P. Winther, Paul Ritchie, Rafi Crohn, and Trevor Macy complete the production architecture. The film’s commercial thesis is straightforward: a contained, R-rated horror entry can deliver theatrical returns at a fraction of tentpole burn, while seeding a villain the broader DCU can later weaponize.

For Warner Bros., the upside is a low-risk, high-margin genre play that expands the franchise’s tonal vocabulary without committing to a nine-figure ensemble spend. If Clayface lands, the studio gains a horror lane it can replicate, and a villain with genuine theatrical equity.

Reviewed by

Chief Reviewer

Ankit Jaiswal

Editorial Director - 7+ yrs

Ankit Jaiswal is the Chief Author, covering Indian cinema and OTT releases with honest, no-filler criticism. An SEO strategist by background, he brings a research-driven approach to film writing, cutting through hype to tell you exactly what's worth your time.